Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Dutasteride may affect testosterone levels, leading to high ferritin and iron levels, which can cause hair loss. High ferritin might be linked to past heavy drinking or hemochromatosis.

The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a study suggesting that sulforaphane may reduce DHT levels and promote hair growth in mice.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.

Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.

Some people see significant hair regrowth using treatments like finasteride and minoxidil, while others experience little to no improvement even with comprehensive treatment plans. Factors such as individual sensitivity to DHT may influence the effectiveness of these hair loss treatments.

A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation is about using Tretinoin with Minoxidil for hair loss treatment, discussing the effectiveness and personal experiences with different concentrations. The image linked in the post received negative reactions for being unpleasant.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.